Oruka Therapeutics (FRA:HQ1) EV-to-EBIT : (As of May. 10, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Oruka Therapeutics's Enterprise Value is €-12.98 Mil. Oruka Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's EV-to-EBIT at this moment.

The historical rank and industry rank for Oruka Therapeutics's EV-to-EBIT or its related term are showing as below:

FRA:HQ1's EV-to-EBIT is not ranked ^*
in the Biotechnology industry.
Industry Median: 5.9
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Oruka Therapeutics's Enterprise Value for the quarter that ended in Dec. 2024 was €0.00 Mil. Oruka Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Oruka Therapeutics's Earnings Yield (Joel Greenblatt) % at this moment.

Oruka Therapeutics EV-to-EBIT Historical Data

The historical data trend for Oruka Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics EV-to-EBIT Chart

Oruka Therapeutics Annual Data

Trend

Dec24

EV-to-EBIT

Oruka Therapeutics Semi-Annual Data
	Dec24
EV-to-EBIT	-

Competitive Comparison of Oruka Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Oruka Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Oruka Therapeutics EV-to-EBIT Calculation

Oruka Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-12.981	/
	=

Oruka Therapeutics (FRA:HQ1) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Oruka Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 )	=	EBIT	/	Enterprise Value (Q: Dec. 2024 )
	=		/	0
	=	%

Oruka Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

ORKA:USA

Address

855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025

Website

https://www.orukatx.com

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines